This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Alexander K. C. Leung, FRCP(Glasg), FRCP (Edin); William Lane M. Robson, MD, FRCPC
Alberta Children's Hospital University of Calgary

JAMA. 1991;266(1):62.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

— In a recent editorial entitled "Gifts to Physicians From Industry,"¹ the Council on Ethical and Judicial Affairs of the AMA outlined important guidelines and recommendations regarding types of appropriate gifts from the pharmaceutical industry and the circumstances under which such gifts can be accepted by physicians.

An important and difficult issue that was not specifically addressed in the guidelines is whether physicians should receive research funding from the pharmaceutical industry. The pharmaceutical industry relies on the expertise of physicians to evaluate the safety and efficacy of its products prior to marketing. Physicians are commonly involved in type 4 clinical trials for new pharmaceutical products. Financial support for these clinical trials is usually provided by the pharmaceutical industry to cover technical and secretarial salaries, equipment and supply expenses, and the time and expertise of the physician. There is concern that some clinical trials may be promotional . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?